Ani Pharmaceuticals (ANIP) Return on Capital Employed (2012 - 2026)

Ani Pharmaceuticals has disclosed Return on Capital Employed across 15 years of filings, most recently posting 10.39% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 10.39%, up 979.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 10.39% (up 979.0% YoY), and the FY2025 annual result was 10.25%, up 1018.0% from the prior year.
• Return on Capital Employed came in at 10.39% for Q1 2026 at Ani Pharmaceuticals, up from 9.69% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 10.39% in Q1 2026 to a low of 9.17% in Q3 2022.
• The 5-year median for Return on Capital Employed is 1.41% (2025), against an average of 1.45%.
• Across the five-year window, Return on Capital Employed tumbled 779 bps in 2022 and jumped 1485 bps in 2023, its largest moves.
• Ani Pharmaceuticals' Return on Capital Employed stood at 5.43% in 2022, then surged by 215 bps to 6.25% in 2023, then tumbled by 99 bps to 0.05% in 2024, then soared by 18015 bps to 9.69% in 2025, then grew by 7 bps to 10.39% in 2026.
• The last three Return on Capital Employed figures came in at 10.39% (Q1 2026), 9.69% (Q4 2025), and 6.51% (Q3 2025), per Business Quant data.